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Abstract It is currently controversial whether remote
ischemic preconditioning (RIPC) reduces the incidence of
acute kidney injury (AKI) in patients undergoing cardio-
vascular interventions. The main objective of this meta-
analysis was to investigate whether RIPC provides renal
protection for patients undergoing cardiac or vascular
surgery. We searched the PubMed database (1966-Oct
2015), Embase database (1966-Oct 2015), Google Scholar,
Cochrane Library, ClinicalTrials Database and Open Grey.
Then we conducted a meta-analysis of the randomized
controlled trials that met the inclusion criteria of our study.
The interventions included use of an inflatable tourniquet
around the limbs or cross-clamping of the iliac arteries
before surgery (RIPC groups) and general cardiovascular
intervention (control groups). The main outcomes exam-
ined included the incidence of AKI; changes in acute
kidney injury biomarkers; and use of renal replacement
therapy. Other outcomes examined included in-hospital
mortality and the lengths of hospital stay and intensive care
unit (ICU) stay. Finally, we screened 26 eligible studies
containing 6699 patients who underwent cardiac or
vascular interventions with RIPC (n = 3343) or without
RIPC (n = 3356). The AKI incidence was decreased in the
RIPC group as was the length of ICU stay. There were no
differences in the changes in AKI biomarkers, use of renal
replacement therapy or in-hospital mortality between the
two groups. Remote ischemic preconditioning may
decrease the occurrence of AKI in cardiovascular surgery
patients. Since studies included have a significant hetero-
geneity, meta-analyses using a stricter inclusion criteria are
needed to clarify the renoprotection effect of RIPC.
Keywords Remote ischemic preconditioning  Acute
kidney injury  Cardiac and vascular interventions 
Meta-analysis
Introduction
Acute kidney injury (AKI) is a serious post-operation
complication in cardiac surgery patients [1]; its incidence
ranges from 3 to 42 % [2–10], and 1 to 5 % of AKI patients
require dialysis therapy [1, 2, 4, 9, 11]. The mortality of
AKI patients has been reported to be as high as 40–80 %
[1, 7, 9]. Although this clinical problem is gaining
increased attention, there are still no efficient methods to
prevent AKI after cardiac and vascular interventions [5, 6,
12–14]. A double-blinded, placebo-controlled multicenter
study conducted by Julier et al. [15] confirmed that
sevoflurane preconditioning reduces the increase in post-
operative plasma cystatin C (Cys C) concentration; how-
ever, that trial did not investigate the relationship between
sevoflurane preconditioning and perioperative AKI
prevalence.
Remote ischemic preconditioning (RIPC) consists of
cycles of transient non-fatal ischemia in one tissue to
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enhance the toleration of a subsequent prolonged fatal
ischemia in distant organs [16]. The protective mechanism
of RIPC to specific organs has been illustrated by several
studies [14, 17, 18]; however, whether remote ischemic
preconditioning has a positive clinical effect on renal
function in cardiac and vascular surgery patients remains
unclear. Some previous randomized controlled trials
(RCTs) showed that RIPC reduces AKI incidence in car-
diac surgery patients, but other studies had conflicting
results. Several previous systematic reviews also demon-
strated controversial results [19–23]. In recent years, more
relevant RCTs have been carried out and published, so we
performed a meta-analysis to verify the effect of RIPC on




Studies that met the following inclusion criteria were
included in this meta-analysis: (1) RCT design; (2) study
participants underwent some type of elective or acute
cardiac or vascular surgery; (3) RIPC intervention,
regardless of the duration or number of cycles; vessel
occlusion models were also included; the control group
intervention was standard treatment without RIPC or with
sham RIPC; and (4) report of the incidence of AKI.
The primary outcome analyzed was the incidence of
AKI. The secondary outcome measures included change in
renal biomarkers after surgery, the use of renal replacement
therapy, in-hospital mortality, the length of hospital stay
and the length of intensive care unit (ICU) stay.
Search strategy
A literature search was conducted after establishing the
inclusion criteria. We searched published articles in the
PubMed (1966-Oct 2015), Embase (1966-Oct 2015),
Google Scholar and Cochrane Library databases. We also
searched ClinicalTrials.gov and Open Grey for unpub-
lished and ongoing trials. There were no language or region
restrictions. The following Medical Subject Heading terms
and text words were used: ischemic preconditioning, car-
diovascular surgical procedures, randomized controlled
trial, controlled clinical trial, remote ischemic precondi-
tioning. Titles and abstracts were screened by two authors
(L-xC, Y-cW) to guarantee their concordance with the
inclusion criteria. Full text screening was conducted by the
same two persons after preliminary screening if the arti-
cle’s eligibility could not be determined by screening the
title and abstract.
Data extraction
Data extraction was performed by another two authors (Y-
yL, SF) using a standardized data extraction form. Dis-
agreements were resolved by a third person who served as
an intermediary (B-jL) and made the final decision. Every
trial was carefully assessed, and the following data were
extracted: patient demographic characteristics, types of
cardiovascular interventions, RIPC protocol, dose of con-
trast medium, AKI definition, incidence of AKI, in-hospital
mortality, length of hospital stay, length of ICU stay,
incidence of kidney replacement therapy, serum or plasma
creatinine levels before and 24 and 48 h after surgery, and
glomerular filtration rates (GFRs) at 24 and 48 h after
surgery.
Fig. 1 Flowchart of article
selection. RCT randomized
controlled trial
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Study validity assessment
The Jadad scale was used to evaluate the methodological
quality of the eligible trials. This scoring standard
examines randomization, blinding, and explanation for
withdrawals and dropouts [24, 25]. The modified Jadad
scale, which includes the additional factor of item allo-
cation concealment, was also used, with a score of 1–3
indicating low quality and a score of 4–7 indicating high
quality [26]. Intention-to-treat (ITT) was also analyzed.
We also judged risk of bias for each included study in
terms of selection bias, performance bias, detection bias
and attrition bias.
Statistical analysis
We mainly utilized the software Review Manager (Rev-
Man) version 5.3 to analyze the extracted data (Copen-
hagen: The Nordic Cochrane Centre, The Cochrane
Collaboration, 2014). Risk ratios (RRs) with 95 % confi-
dence intervals (CIs) were calculated for dichotomous
outcomes, and mean differences with 95 % CI were cal-
culated for continuous outcomes. Statistical heterogeneity
was assessed using the v2 test, and we determined the
percentage of total variation across studies using the Hig-
gins I2 statistic. We compared our primary analysis with
random-effects models using the Knapp–Hartung method
to determine the robustness of the pooled effects.
Results
Search results
The search initially identified 965 articles; 234 duplicated
articles and 250 animal studies were excluded. After title
and abstract screening, 183 nonrandomized trials were
excluded. Then, by full-text assessment of the remaining
articles, we finally identified 26 eligible randomized con-
trolled trials [14, 16, 27–50] (excluded articles: no target
population: n = 8; no target outcomes: n = 255; no target
interventions: n = 2; protocol only: n = 7, Fig. 1).
Study characteristics
A total of 6699 patients were enrolled in the 26 included
studies, with 3343 patients randomized to the RIPC group
and 3356 randomized to the control group. Sixteen studies
examined cardiac surgery [14, 16, 28, 29, 31–33, 36, 39,
40, 43, 46–50], six studies examined percutaneous coro-
nary intervention [30, 34, 35, 37, 41, 45], and four studies
examined vascular surgery [27, 38, 42, 44]. The RIPC
protocols were different between studies: 24 studies used
an inflatable tourniquet around the limbs [14, 16, 27–50],
and two studies used cross-clamping of the iliac arteries
[27, 44]. The participants in one of the studies were chil-
dren [39], while those of all other studies were adults.
Seven studies applied contrast medium [30, 34, 35, 37, 41,
42, 45]. The key characteristics of the included studies are
shown in Table 1.
Quality assessment
Two authors (YY, X-bL) independently assessed the
quality of the 26 studies using the Jadad scale and the
modified Jadad scale. Twenty-one (80 %) trials [14, 16,
27–29, 32–34, 36–40, 42–45, 48–50] had a relatively high
methodological quality based on the Jadad scale, while 19
(73 %) trials [14, 16, 27, 28, 30, 32–36, 38, 40, 42, 44, 45,
47–49] had a relatively high methodological quality based
on the modified Jadad scale. The randomization methods
were adequate in 20 studies. Allocation concealment was
adequate in 16 studies. Blinding was adequate in ten
studies (Fig. 2). All studies had clear explanations for
withdrawals and dropouts. Only six studies did not meet
the ITT analysis criteria. The details of the quality
assessment are shown in Table 2.
Outcomes
Incidence of AKI
Data regarding AKI incidence were available in all 26
studies, and the rate of AKI was significantly lower in the
RIPC group than in the control group [p = 0.01; RR 0.79
(95 % CI 0.66–0.95), Fig. 3] (random model). However, it
should be noted that different AKI definitions were applied
in different studies. The AKI definitions used included the
AKI Network (AKIN) criterion [16, 29, 38, 43, 47, 50], the
Kidney Disease: Improving Global Outcomes (KDIGO)
criterion [14, 41, 48], the RIFLE criterion [39, 46], post-
operative serum creatinine C0.5 mg/dl or C25 % above
baseline [30, 34, 37, 40, 45], and others [27, 28, 31–33, 35,
36, 42, 44, 49]. We performed subgroup analyses based on
the different AKI definitions. RIPC reduced AKI incidence
as defined by a postoperative serum creatinine C0.5 mg/dl
or C25 % above baseline [p = 0.0002; RR 0.42
(0.27–0.67); heterogeneity v2 = 3.89, I2 = 0 %, p for
heterogeneity = 0.42]. However, RIPC did not reduce AKI
incidence in the subgroups in terms of the other AKI def-
initions: AKIN criterion [p = 0.56; RR 0.87 (0.56–1.37);
heterogeneity v2 = 12.22, I2 = 59 %, p for heterogene-
ity = 0.03], KDIGO criterion [p = 0.32; RR 0.83
(0.58–1.20); heterogeneity v2 = 6.76, I2 = 70 %, p for
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heterogeneity = 0.03], RIFLE criterion [p = 0.37; RR
0.87 (0.64–1.18); heterogeneity v2 = 0.06, I2 = 0 %, p for
heterogeneity = 0.81], and others [p = 0.34; RR 0.83
(0.56–1.22); heterogeneity v2 = 18.85, I2 = 52 %, p for
heterogeneity = 0.03] (Fig. 4).
In-hospital mortality
In-hospital mortality was reported in 16 trials [14, 27, 28,
30, 31, 33, 36, 38–40, 42–44, 46, 47, 49], and there was no
significant difference in mortality between the RIPC and
control groups [p = 0.97; RR 1.01 (0.63–1.61); hetero-
geneity v2 = 11.84, I2 = 0 %, p for heterogeneity = 0.54,
Fig. 5].
Change in renal biomarkers
At 24 and 48 h after surgery, serum creatinine level was
reported in five trials [29, 36, 41, 42, 44] and five trials [29,
35, 42, 44, 45], respectively. GFR was reported at 24 and
48 h after surgery in four trials [29, 35, 42, 44]. There were
no significant differences between the two groups in serum
creatinine (Scr) level or GFR at 24 or 48 h after surgery
(Fig. 6).
Initiation of renal replacement therapy
Renal replacement therapy was reported in 15 trials [14,
27, 29–33, 38–40, 42, 44, 47, 50], and no significant dif-
ference was observed in the performance of renal
replacement therapy between the RIPC group and the
control group [p = 0.96; RR 1.02 (0.45–2.30); hetero-
geneity v2 = 21.35, I2 = 58 %, p for heterogene-
ity = 0.01, Fig. 7].
The lengths of hospital stay and ICU stay
Four trials reported the length of hospital stay [29, 32, 36,
40], and three trials reported the length of ICU stay [29, 32,
36]. There was no significant difference in the length of
hospital stay between the two groups [p = 0.56; mean
difference 0.37 (-0.87 to 1.61); heterogeneity v2 = 5.64,
I2 = 47 %, p for heterogeneity = 0.13]. The length of ICU
stay was remarkably reduced in the RIPC group
[p = 0.008; mean difference -0.54 (-0.95 to -0.14);
heterogeneity v2 = 2.08, I2 = 4 %, p for heterogene-
ity = 0.35, Fig. 8]; however, the number of trials was too
small to observe a statistically significant difference.
bFig. 2 Risk of bias table: green low risk of bias, yellow unclear risk
of bias, red high risk of bias (color figure online)
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Table 2 Quality assessment of included trials
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Subgroup analysis
This meta-analysis of AKI incidence showed that RIPC
reduces the perioperative incidence of AKI in cardiac and
vascular surgery patients. However, there was high statis-
tical heterogeneity among the included trials (heterogeneity
v2 = 46.67, I2 = 53 %, p for heterogeneity = 0.002,
Fig. 3). Since the different AKI definitions are based on
different changes in serum creatinine from baseline, and
contrast applications are specific clinical settings that could
influence kidney function, we performed subgroup analy-
ses of these two potential covariates. The results of the
subgroup analysis were marginally significant (Figs. 4, 9);
however, meta-regression analysis indicated that different
AKI definitions were not the covariate contributing sig-
nificantly to heterogeneity on the risk estimate for AKI
incidence [coefficient -0.39 (-1.15 to 0.38); p = 0.56].
We also did the meta-regression of contrast application
conditions, and found that there was statistically significant
difference in the risk estimate for AKI incidence [coeffi-
cient -0.22 (-0.51 to 0.07); p = 0.039].
Sensitivity analysis
We used a fixed model and random model to analyze the
different outcomes, and none of the results of the examined
outcomes were different for these two models. These two
models both indicated that remote ischemic precondition-
ing reduced the incidence of AKI in patients undergoing
cardiovascular interventions.
Discussion
Many randomized controlled trials on remote ischemic
preconditioning have been performed, and RIPC has been
shown to ameliorate heart ischemia–reperfusion injury
[51]. The commonly used RIPC methods are the placement
of an inflatable tourniquet around the limbs and the cross-
clamping of the iliac arteries, both of which are noninva-
sive and nonpharmacological procedures. Cardiac and
vascular surgery patients have a high risk of AKI [1], and
AKI increases mortality [2]. However, currently, there are
Fig. 3 Meta-analysis of AKI incidence between RIPC and control groups. CI confidence interval, KH Knapp–Hartung method
26 J Nephrol (2017) 30:19–33
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no effective clinical strategies for preventing the occur-
rence of AKI [5, 6, 12–14]. Remote ischemic precondi-
tioning is a hot research area, and many researchers have
applied this method to prevent AKI in cardiovascular sur-
gery patients in recent years. However, disappointingly, the
results of those studies do not clearly show whether RIPC
Fig. 4 Subgroup analysis for studies with different AKI definitions. CI confidence interval, KH Knapp–Hartung method
J Nephrol (2017) 30:19–33 27
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reduces AKI incidence in cardiac and vascular surgery
patients. Meta-analyses performed by other teams also
failed to reach a consistent conclusion. Yasin et al. [21] and
Yang et al. [22] performed meta-analyses, and they both
found no statistically significant differences in AKI inci-
dence between cardiovascular surgery patients who did and
did not undergo RIPC. However, a meta-analysis of 13
trials conducted by Yang et al. (1134 participants) showed
that RIPC decreased the risk of AKI in cardiac and vascular
surgery patients [23]. In addition, meta-analyses of other
indices of renal impairment have not reached consistent
conclusions [19, 21, 22, 52–54]. These inconsistent results
may be due to the limitation of small sample size; there-
fore, larger samples and meta-analyses are needed.
This meta-analysis included 6699 participants in 26
trials who underwent cardiac or vascular interventions and
were randomized to a RIPC group or control group. The
results of our analysis reveal that RIPC significantly
reduced AKI incidence in patients undergoing cardiac or
vascular interventions [p = 0.01; RR 0.79 (0.66–0.95)].
Because there was high statistical heterogeneity among the
included trials, conclusions based on these results should
be made with caution. The meta-analysis by Yang et al.
indicated that the contrast medium intervention was not a
covariate that significantly contributed to the heterogeneity
in the risk estimate for AKI incidence, but the subgroup
analysis of the contrast medium intervention in our study
showed marginal statistical significance (Fig. 9). So we
performed a meta-regression analysis, and the result
showed that the contrast medium intervention was a
covariate that significantly contributed to heterogeneity in
the risk estimate for AKI incidence.
Although AKI incidence was reduced in the RIPC
group, there were no significant differences in mortality
or renal biomarkers between the two groups. Considering
that not all of the included trials reported mortality or
renal biomarkers, it is difficult to confirm whether RIPC
has a kidney protective effect in patients undergoing
cardiovascular interventions. Furthermore, other more
sensitive indicators of early kidney damage, such as
neutrophil gelatinase-associated lipocalin (NGAL) [55],
Cys C [56] and urine output, were not available. Like-
wise, the use of renal replacement therapy and the length
of hospital stay were not significantly different between
the two groups. Length of ICU stay was shorter in the
RIPC group, but that finding cannot be considered con-
clusive because only three trials reported valid data
regarding ICU stay.
One trial only included patients without diabetes mel-
litus (DM) [43], whereas another trial only included
patients with DM [41], and as DM is a potential risk factor
for postoperative acute kidney injury in patients undergo-
ing cardiac and vascular surgeries [57] the findings of our
study may not be generalizable to non-diabetic patients.
Fig. 5 Meta-analysis of in-hospital mortality between RIPC and control groups. CI confidence interval, KH Knapp–Hartung method
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Our meta-analysis has some limitations. First, surgery
type, anesthesia and premedication varied between trials,
which may have generated different risk levels of periop-
erative acute kidney injury incidence. Second, there was a
high level of heterogeneity in the demographic data of the
patients among the included trials: Also, the baseline serum
creatinine level varied considerably between studies, which
may indicate differences in basic renal function between
studies. We should also note that the patients in the trial by
Pedersen et al. [39] were children, while those in the other
25 studies were adults. Third, we did not limit this meta-
analysis to studies that examined one specific RIPC pro-
cedure: two of the included studies performed cross-
clamping of the iliac arteries [27, 44] instead of using an
inflatable tourniquet around the limbs. Fourth, different
AKI definitions were applied by the researchers of the
different studies. All of these limitations may explain the
high heterogeneity between studies besides the contrast
application. Finally, only ten studies [14, 16, 28, 33, 36, 38,
40, 45, 46, 49] were double-blind, and we think that the
single-blind and non-blind studies may have influenced the
results of this meta-analysis.
Fig. 6 Meta-analysis of mean differences in kidney biomarker levels
between RIPC and control groups. a Serum creatinine (Scr) levels at
24 h postoperatively; b Scr levels at 48 h postoperatively;
c glomerular filtration rates (GFRs) at 24 h postoperatively; d GFRs
at 48 h postoperatively. CI confidence interval, KH Knapp–Hartung
method, SD standard deviation
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Fig. 7 Meta-analysis of the use of renal replacement therapy between RIPC and control groups. CI confidence interval, KH Knapp–Hartung
method
Fig. 8 Meta-analysis of e length of in-hospital stay and f length of intensive care unit (ICU) stay between RIPC and control groups. CI
confidence interval, KH Knapp–Hartung method
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Conclusion
Remote ischemic preconditioning can reduce the postopera-
tive occurrence of acute kidney injury in cardiac and vascular
surgery patients. However, considering the high hetero-
geneity among the 26 trials analyzed, we cannot draw a
definitive conclusion regarding the value ofRIPCat this time.
A larger sample using a uniform AKI definition and RIPC
method is needed to reach a more definitive conclusion.
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